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ABSTRACT The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch
a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European
countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and
will add value to existing public health knowledge by: 1) proposing a common framework of care pathways
for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives;
2) informing cost-effective policy development, strengthening in particular those on smoking and
environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy;
4) having a significant impact on the health of citizens in the short term (reduction of morbidity,
improvement of education in children and of work in adults) and in the long-term (healthy ageing);
5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare
burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life.
In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYS-
ICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and
Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers).
@ERSpublications
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Introduction
Chronic respiratory diseases: from guidelines to policies
Chronic respiratory diseases are major non-communicable diseases [1]. Asthma and allergic diseases occur
throughout the life cycle and can begin during pregnancy and childhood. In Europe, they affect 30 million
children and adults under 45 years of age. Chronic obstructive pulmonary disease (COPD) has an estimated
annual death rate of over 4 million people globally. Among the European Union (EU) member states,
asthma accounted for an average of 53 hospital admissions per 100 000 population in 2009, and the average
COPD-related admission rate was 184 [2]. The annual direct and indirect costs in the 28 EU countries due
to COPD or asthma are estimated at J48 billion and J34 billion, respectively [2]. Chronic respiratory
diseases affect active and healthy ageing. Asthma in children or adults is a common risk factor for COPD in
adults [3, 4].
Guidelines for COPD [5] and rhinitis–asthma comorbidity [6] exist using the GRADE (Grading of
Recommendations Assessment, Development and Evaluation) approach [7, 8]. Global strategies have also
been proposed for the prevention and control of asthma [9] and COPD [10]. However, in older adults, it is
often difficult to differentiate between asthma and COPD [11], and none of the current guidelines appear to
have a specific module for older people [12].
Effective strategies are needed to reduce chronic respiratory disease burden. National programmes (e.g. the
Finnish, Czech or Portuguese asthma or COPD programmes [13, 14]) can be cost-effective [15], but they
are insufficiently implemented in the EU. Integrated care pathways (ICPs) for COPD (QS10) exist in the UK
(National Institute for Health and Care Excellence, NICE) [16], in France (Haute Autorité de Santé) and in
the Netherlands [17–19], but ICPs for asthma or asthma and rhinitis comorbidity do not exist. Asthma
quality standards for asthma (QS25) have been published by NICE [20]. These are specific, concise
statements that act as markers of high-quality, cost-effective patient care. Moreover, some initiatives are
aimed at also incentivising good practice and improving implementation (i.e. remuneration based on
performance indicators). In the UK, the Quality and Outcomes Framework has four asthma-specific
performance indicators which are explicitly linked to the subsequent remuneration of providers [21].
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In low-resource settings, some successful attempts to combine all non-communicable diseases into one
single action plan have been developed [22–24] for the implementation of the World Health Organization
(WHO) non-communicable disease action plan. However, such combined plans are not available for the
management of non-communicable diseases in high-resource settings.
The Polish Presidency of the EU Council (3051st Council Conclusions) has made the prevention, early
diagnosis and treatment of asthma and allergic diseases a priority to reduce health inequalities [25, 26]. The
3206th Cyprus Council Conclusions recommended that the diagnosis and treatment of chronic diseases
should be initiated as early as possible to improve active and healthy ageing [27]. A debate at the European
Parliament (Cyprus Presidency of the EU Council, 2012) recommended early diagnosis and management of
chronic respiratory diseases in children in order to promote active and healthy ageing [28].
Protective and risk factors
Chronic respiratory diseases and other non-communicable diseases often share environmental risk factors
(e.g. tobacco, nutrition, indoor and outdoor air pollution, and sedentary lifestyle) [1, 29], leading to
sustained local and systemic inflammation [30, 31] and impaired ageing. Tobacco smoking is the best-
identified risk factor for many non-communicable diseases, including chronic respiratory disease.
The prevention and control of chronic diseases could be considered sequentially before the disease has been
identified in order to 1) prevent its onset (health promotion and primary prevention), and 2) better control
and prevent the short- and long-term consequences after its onset (secondary and tertiary prevention
and control).
Starting in early childhood, the foundations for healthy or weakened respiratory organs are laid from a
political perspective to feed into the goals of the Europe 2020 strategy as well as healthy and active ageing [32].
Multi-sectoral prevention, including policy change, regulation and market intervention, is of the highest priority.
Integrated care pathways
ICPs, also known as clinical pathways or care pathways, are structured multidisciplinary care plans which
detail essential steps in the care of patients with a specific clinical problem [33]. They promote the
translation of guidelines into local protocols and their subsequent application to clinical practice. An ICP
forms all or part of the clinical record, documents the care given, and facilitates the evaluation of outcomes
for continuous quality improvement [34]. ICPs empower patients as well as their health and social carers.
ICPs differ from practice guidelines as they are utilised by a multidisciplinary team, and focus on the quality
and co-ordination of care. ICPs need to record variations from planned care [35]. An ICP is intended to
inform and encourage thought and adaptation. Clinicians are free to exert their own professional judgments
as appropriate. However, any alteration to the practice identified within the ICP must be noted as a variance
[36]. Variance analysis may be used to optimise the ICPs linked with pay-for-performance [37–40], audit
and feedback, and integration of recommendations with electronic medical records.
ICPs are already the standard of care in different areas of medicine, such as oncology [41] or palliative care
[42]. Some have already been proposed for asthma or COPD.
The care pathways simulator, a discrete event simulation software programme, helps to view the system
from the perspective of the task, job or patient, rather than of the function [43]. Service redesign, targeted at
improving services, can bring benefit to patients, carers, staff and National Health Service (NHS) trusts [44].
European Innovation Partnership on Active and Healthy Ageing
European innovation partnerships attempt to enhance EU competitiveness and to tackle societal challenges
by fostering innovation. They address the weaknesses in EU research and innovation that complicate the
discovery or exploitation of knowledge and may hinder innovation into the market place.
Active and healthy ageing is a major societal challenge common to all countries and to all populations [45].
Ageing is intertwined with socioeconomic inequalities [46], is an under-appreciated cause of poverty and
hinders economic development, particularly affecting underserved populations and females. Active and
healthy ageing needs to be promoted very early in life to be successful.
The European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) is deployed in three
areas and six action plans [47]:
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N Prevention of diseases and health promotion
N Innovative ways to ensure that patients adhere to their treatments (A1)
N Innovative solutions for personalised health management, with focus on falls prevention (A2)
N Action for preventing functional decline and frailty, with a particular focus on malnutrition (A3)
N Care and cure: scaling up and replication of successful innovative integrated care models for chronic
diseases among older patients, such as through remote monitoring (B3)
N Active and independent living of older adults by improving the uptake of interoperable independent
living solutions including guidelines for business models (C2)
N Horizontal topics: networking and knowledge sharing on innovation for age-friendly environments (D4)
The EIP on AHA aims to provide a framework for supporting bottom-up innovations and a forum for
professional collaboration. The partners work on a voluntary basis to pool their knowledge and expertise in
order to deploy, scale-up and replicate innovative health and care services.
The implementation of the strategy and action plan of WHO Europe on healthy ageing [48] has synergies
with a number of the priorities and actions identified in the strategic implementation plan of the EIP on
AHA, and shares its positive vision of ageing.
Objectives of AIRWAYS-ICPs
The general objective of AIRWAYS-ICPs is to develop multi-sectoral ICPs for CRDs used across European
countries and regions in order to 1) reduce the burden of the diseases, 2) promote active and healthy ageing,
and 3) create a care pathways simulator tool which can be applied in older adults. AIRWAYS-ICPs will not
duplicate existing EU prevention programmes in chronic respiratory diseases (e.g. anti-smoking) but will
strengthen them where appropriate.
The aim of AIRWAYS-ICPs is to propose central unifying themes and an overall potential to gain political
leverage in the current environment and to better understand and manage the spectrum of care for patients
with chronic airway disease in European countries and regions. It will also aim to generalise the approach to
the uniform definition of severity, control and risk of severe asthma presented to the WHO [49], as well as
of allergic diseases [50], in order to develop a uniform risk stratification usable for chronic respiratory
diseases in most situations.
AIRWAYS-ICPs will propose a feasible, achievable and manageable project from science to guidelines
(fig. 1) using existing networks and partners committed to Action Plan B3 of the EIP on AHA.
Specific objectives include the following:
1) To collect guidelines and ICPs that exist in European countries and regions for airway diseases (asthma,
COPD and rhinitis).
2) To strengthen prevention and health promotion for airway diseases.
3) To stratify patients with severe chronic respiratory diseases.
4) To understand AIRWAY diseases in children and adolescents and to develop ICPs (P.A.R.IS).
Outcomes
Implement
best practices
Problem framing and
goal setting
Raise new issues and
level of ambition
Evaluate critically and
identify causes of failure
Participate in operationalising
Collaborate and challenge
Address different audiences
FIGURE 1 From science to guidelines
and best practices.
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5) To develop important questions on chronic respiratory diseases for older people.
6) To understand and overcome barriers in chronic respiratory disease management.
7) To develop ICPs for rhinitis and asthma comorbidity across the life cycle, and for COPD and asthma in
older people, combining preventive and disease control strategies based on existing national (or regional)
programmes (e.g. Finnish or Portuguese asthma, COPD and allergy programmes).
8) To develop a simulation tool of ICPs for rhinitis and asthma comorbidity that could be applied to older
people and to redesigning care pathways.
9) To tackle chronic respiratory diseases across the life cycle, placing a particular interest in the cultural and
social aspects of the diseases in a project centred on the patient.
10) To implement multi-sectoral, multi-country initiatives to allow the practical use of AIRWAYS-ICPs by
European countries and regions, and beyond to other countries, for cost-effective policies on the prevention
and control of asthma, COPD and allergy.
AIRWAYS-ICPs working group
The AIRWAYS-ICPs working group has included the WHO Global Alliance against Chronic Respiratory
Diseases and WHO Collaborating Center (2001–2013) working groups (64 countries). Moreover, we have
attempted to include as many European countries as possible (23 EU countries) and it should be noted that
Serbia, Croatia, Slovenia and Slovakia, who were not included in the previous study groups, are now
included with a large number of representatives. Moreover, we have enhanced the study group by including
social carers and public health researchers. Patients are well represented. In some countries, the names of the
representatives have been proposed by governmental organisations. Finally, through the EIP on AHA,
European Regions and Health Authorities (EUREGHA), other representatives were included, in particular
NHS England, Scotland and Northern Ireland, as well as Wallonie and Southern Denmark. The working
group now includes all the stakeholders required for the development of multi-sectoral ICPs.
AIRWAYS-ICPs
1) To collate existing ICPs, national programmes and guidelines
Tools used in the 28 EU countries and other European countries will be collected with regards to ICPs for
COPD, asthma and rhinitis. This approach will be deployed to other countries. A repository is being
developed by the EIP on AHA to collect projects such as:
1) Good practices of the B3 Action Group on integrated care.
2) The Finnish plans for asthma [13], allergy [51] and COPD [14] which are considered to be the
prototypes of national plans for chronic respiratory diseases. Polastma (Poland) is, in particular, derived
from the asthma plan.
3) The Portuguese National Programme for Respiratory Diseases (PNDR), the first national programme to
include all respiratory diseases.
4) Care pathways provided by national institutions (e.g. NICE in the UK or the Haute Autorité de Santé in France).
5) The WHO guidelines for asthma and COPD in low-income settings.
6) A common approach to severe asthma and allergic diseases.
7) International Primary Care Respiratory Group mapping of national guidelines used by primary care for
COPD, asthma, rhinitis, community-acquired pneumonia, obstructive sleep apnoea and smoking cessation [52].
2) To strengthen EU policies for the prevention of chronic respiratory diseases
The European Commission addresses chronic respiratory disease as a key priority and includes legislation
on tobacco consumption and ambient air quality, work on climate change, and actions under the European
Environment and Health Strategy. These policies tie in with active Commission support for the current
United Nations process to address non-communicable diseases and related socioeconomic and
environmental determinants. There is an urgent need to strengthen prevention and health promotion, in
particular for smoking cessation (‘‘Health for Growth’’ public health programme), improved physical and
social environment, and promotion of lifestyle of beneficial value for ‘‘whole of society’’ and ‘‘vulnerable
groups’’ in particular [53].
INTEGRATED CARE PATHWAYS FOR AIRWAY DISEASES | J. BOUSQUET ET AL.
DOI: 10.1183/09031936.00014614310
3) Stratification of patients with severe chronic respiratory diseases
Severity is the intrinsic severity of the disease process, control is the degree to which therapy goals are met,
and responsiveness is the ease with which control is achieved by therapy. The concept of severity and
control has been largely developed for asthma in guidelines [54]. The uniform definition of severe asthma
[55] presented to the WHO [49] used an approach derived from the National Asthma Education and
Prevention Program Expert Panel Report 3 guidelines [56]. This approach has also been used for all allergic
diseases (fig. 2) [50] and may be used for COPD (table 1).
The stratification of patients with chronic respiratory diseases can be generalised using the approach of the
uniform definition of severe asthma presented to the WHO [55], in order to have a uniform definition of
severity, control and risk usable in most situations. This uniform definition will make it possible to better define
the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology),
public health purposes and the development of novel therapies targeted to better defined phenotypes.
4) Understanding airway diseases in children and adolescents and developing ICPs (P.A.R.IS)
Allergic diseases and asthma often start early in life, and most patients will have developed disease before the
age of 18 years. It is therefore important to understand the risk factors and mechanisms underlying allergic
chronic respiratory diseases and asthma in childhood, as well as to determine the gaps in the management
of these diseases in preschool children, school children and adolescents. The prevention of early diagnosis
and the management of chronic respiratory diseases in children is vital for the improvement of active and
healthy ageing.
Within the framework of the EIP on AHA, the European Academy of Allergy and Clinical Immunology
(EAACI) has decided, in collaboration with Allergic Rhinitis and its Impact on Asthma (ARIA), to develop a
programme to better understand AIRWAY diseases in children and to propose a framework for the
development of ICPs in this age group, considering rhinitis and asthma as a single entity.
The Allergy Sentinel Network, approved by the European Parliament, will be developed in Paris [28].
5) Development of important questions on chronic respiratory diseases for older people
Clinically important questions on the diagnosis and management of chronic respiratory diseases in older
adults will be defined using a three-step Delphi process. The questions include COPD, asthma, rhinitis and
chronic respiratory disease comorbidities. Multi-sectoral experts and patients are included.
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FIGURE 2 Decision-making steps for the stratification of severe allergic disease, with correlating action steps for
management. Reproduced from [50] with permission from the publisher.
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First Delphi round: experts were asked to propose the three major problems they would like to have
answered concerning disease in older people, including comorbidities.
Second Delphi round: the questions were assessed by a group of four experts (two methodologists) to check
for redundancy among the questions proposed (similar wording).
Third Delphi round: the questions were sent to the group for agreement.
Fourth Delphi round: the harmonised questions will be sent to 60 experts who will rank them.
The prioritised questions include: 1) asthma in older people; 2) COPD in older people; 3) rhinitis in older
people; 4) comorbidities of asthma and COPD in older people; and 5) how paediatric interventions have an
impact on ageing associated with respiratory diseases.
The list of questions will also be customised in order to be applicable to all countries and targeted to low, middle
and high-income settings within which socioeconomic and health problems differ. The third Delphi round will
be reviewed by two expert panels: one from developing countries and another from developed countries.
The prioritised questions will be answered after a review of available evidence using the GRADE approach.
Further to the first completed steps, it was felt that a better definition was needed for airway diseases and
how they cluster in comorbidities (respiratory and non-respiratory). There are likely to be differences
within the life cycle.
TABLE 1 Stratification steps for severe asthma and chronic obstructive pulmonary disease (COPD)
Asthma COPD
Underdiagnosis Common
If asthma is not diagnosed, severe exacerbations
can occur
Asthma deaths mostly occur in untreated patients
In occupational asthma, early diagnosis is needed
Extremely common
Patients usually consult when they have (very)
severe disease or an exacerbation
If diagnosed earlier, smoking cessation measures
could be initiated and prevent the worsening of
COPD and comorbidities
Effective treatment
Preventive treatment Asthma prevention is not effective, except in some
cases, such as occupational asthma
Smoking cessation effective (at least when
started early)
Drugs Inhaled corticosteroids and b2-agonists very
effective on symptoms and control
At regular doses, no treatment is clearly effective
on remodelling
Somewhat effective on symptoms
High variability due to different COPD phenotypes
(e.g. chronic bronchitis and emphysema)
Modestly effective on exacerbations, possibly
because phenotypes are not well characterised
and COPD encompasses several different
phenotypes which may respond differently
to drugs
No treatment effective on decline of lung function
Treatment availability and
affordability
A global problem
Differential diagnosis Many ‘‘uncontrolled’’ patients with current
asthma medications have asthma and another
disease or another disease (e.g. bronchiectasis)
Many COPD patients have a differential diagnosis
(including lung cancer)
Compliance and literacy For drugs For smoking cessation
Inhaler misuse A global problem
Smoking and other risk factors A global problem
Comorbidities Severe nasal problems (e.g. polyposis) may
impair asthma control
Key problem: many patients with COPD have
severe comorbidities that may not even
be diagnosed
Many deaths are due to comorbidities
Mood, depression and socioeconomic
status
A global problem
Controlled disease with high
intensity treatment
A large number of patients fall into this category
If treatment is stopped, exacerbations can
occur quickly
Phenotypes are not well characterised and COPD
encompasses several different diseases (e.g.
chronic bronchitis and emphysema) that may
respond differently to drugs
Phenotypic characterisation is urgently needed
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6) Understanding and overcoming barriers in chronic respiratory disease management
Many barriers exist and prevent the deployment and use of a non-communicable disease global approach in
different settings and countries.
7) Development of ICPs for rhinitis and asthma comorbidity across the life cycle, and for COPD,
asthma and comorbidities in older people
1) To develop multi-sectoral ICPs which can be used across Europe and in other countries.
2) For asthma and rhinitis comorbidity, the P.A.R.IS approach (EAACI–ARIA) will be used in children and
the ARIA approach in adults and older people.
3) A combined approach to asthma and COPD has been proposed for older people, as the two diseases
overlap and are often difficult to differentiate, particularly at the primary care level. Moreover, non-respiratory
comorbidities will be included since older patients often have several diseases with poly-pharmacy.
4) To combine strategies for prevention and control.
5) To place a special emphasis on older and/or underserved patients.
6) To implement cost-effective policies for the prevention of chronic respiratory diseases.
7) To promote active and healthy ageing. AIRWAYS-ICPs places a particular interest in cultural and societal
aspects of the diseases in a project centred on the patient.
8) Interactions will take place between several sections of AIRWAYS-ICPs in order to develop ICPs (fig. 3).
Health technology assessment will lead to recommendations that will be evaluated in each country (or EU
region) in order to develop multi-sectoral ICPs which may differ depending on the differences within the
health systems, and on the socioeconomic and political priorities of the different countries.
Repository
Existing ICPs for chronic 
respiratory diseases
List of prioritised questions
Questions on
chronic respiratory diseases
in older people
Health technology
assessment
ICP development
at local, regional or 
national levels
Recommendations for prioritised questions
FIGURE 3 Development of integrated care pathways (ICPs).
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8) Redesign care pathways using simulator tools (in older people)
Health costs associated with the long-term care of older people have increased in all countries. Computer-
based simulation tools may provide integrated care services to older people. The simulation is used for
decision-making in healthcare systems by increasing efficiency and reducing unnecessary cost, while
maintaining or improving quality of care [57]. It is linked to the processes of change or reform of the system
[58], and is used as a tool to address the complexity of healthcare systems (healthcare ecosystem) in which
all stakeholders interact (patients, managers, policy makers and professionals). Examples are applied to
infectious diseases [59]. The simulation allows the identification of treatment effects in longitudinal
healthcare data [60], preventing technology-induced errors in healthcare [61]. In the area of ‘‘AIRWAYS
ICPs’’, computational analysis has been used to analyse the role of asthma in airway mechanics parameters [62].
LTCMAS (Long-Term Care Multi-Agent Systems) [63] is a simulator that, as a starting point, used a
holistic model of care systems for people that need long-term care, the Sustainable Socio-Health Model
(SSHM). The implementation of the simulator on the Jason multi-agent platform allows the tool to include
human interactions, preferences and social abilities that take place between older people and the staff of
healthcare systems (health and social workers). The use of this multi-agent platform provides the required
scalability for simulating population sizes of different orders of magnitude. The closed-loop design of the
proposed simulator permits repeated simulation of successive interactions of the target population with the
healthcare system. The simulator may forecast the long-term effects of different policies on the considered
population as well as on the healthcare system.
Using the Spanish simulation tool LTCMAS [63] as a prototype, a new version will be adapted to the
AIRWAYS patient group (LCT+ AIRWAYS ICPs). LCT+ AIRWAYS ICPs will be available in primary care
centres through health information systems to assist physicians in the stratification of patients and choice of
pathways, including an attempt to include resource use/cost implications.
9) Tackling chronic respiratory diseases across the life cycle
Pre-natal and early-life events have a major impact on the development of chronic diseases in adults [64, 65]
and older people, including diabetes [66], coronary heart diseases [67], asthma [68], COPD [3] or
neurodegenerative diseases [69]. A better understanding of these links will make it possible to propose
effective novel prevention strategies to promote active and healthy ageing.
The developmental origin of ageing is on the EU political agenda. The Polish Priority of the EU Council
(2011) promoted the recognition, prevention and management of chronic respiratory diseases in children to
ultimately affect healthy ageing [26]. The developmental determinants of non-communicable diseases in
ageing were reinforced during the Cyprus Presidency of the EU Council (2012), which proposed to fight
against non-communicable diseases across the life cycle [27]. A meeting at the European Parliament,
organised by the Region Languedoc Roussillon and under the auspices of the Cyprus EU Priority
(November 2012), was focussed on chronic respiratory diseases [28].
In order to find novel health promotion strategies in non-communicable diseases and to promote value
creation, pre-natal and early life events were discussed in a meeting on December 2–3, 2013 by the Region
Languedoc Roussillon and under the auspices of the frame of Action B3 of the EIP on AHA.
10) Multi-sectoral, multi-country initiative
Members of each European country will be involved in a multi-sectoral approach: primary and secondary
care, healthcare professionals (including pharmacists and nurses), social carers, patients and policy makers.
Patients’ organisations and major European scientific societies are partners of the WHO Collaborating
Centre for Asthma and Rhinitis for this initiative. EUREGHA will help to deploy AIRWAYS-ICPs in the EU
regions. Partners outside the EU will also be involved in the initiative. Education and coaching for all
stakeholders with patients’ organisations will be developed.
Interactions with the private sector have already been established with, as an example, Eurobiomed (www.
eurobiomed.org; Commitment for Action B3 Action Plan), the focal point for the economic growth of
MACVIA-LR (Contre les Maladies Chroniques pour un Vieillissement Actif; Fighting Chronic Diseases for
Active and Healthy Ageing).
Added value
AIRWAYS-ICPs is a demonstration project that follows the recommendations of the EU (Council
Conclusions) [25, 26] and which may be the model for ICPs in other chronic diseases for Action Plan B3 of
the EIP on AHA.
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The project does not duplicate actions that can be taken at the country level, but rather highlights problems
that are not sufficiently addressed, and facilitates or enables rectification of these needs. As an example,
fewer than 10 EU countries have a national asthma plan under the auspices of the Ministry of Health.
Moreover, in many European regions, although healthcare is delivered by regions, the existence of regional
plans is scarce.
AIRWAYS-ICPs will be built using the solutions for chronic respiratory diseases that already exist in
countries or regions, as well as with the expertise of health professionals across Europe and beyond. The
solutions that have been validated by professionals or that have already evidenced their success will be
promoted in order to reduce fragmentation.
This project responds to the 3053rd EU Council conclusions: ‘‘innovative approaches for chronic diseases in
public health and healthcare systems’’ adopted on December 7, 2010 and to the United Nations High Level
meeting (2011). Asthma and allergic diseases are common chronic respiratory diseases and 200 million
subjects are affected in Europe. Furthermore, the project uses ICT – innovative simulation tools. It focuses
on the conclusions of the 3131st session of the EU Council (2011) on the Prevention and Control of CRDs
in Children. Asthma plans are particularly effective in underserved populations and attempts will be
undertaken to reduce health inequities.
The project will help to achieve the objective of an active ageing, and responds to the 3206th Council
Conclusions [27] that recommend the initiation of early diagnosis and treatment of chronic diseases as early
as possible in order to improve active and healthy ageing.
The aim of AIRWAYS-ICPs is to improve healthy life years and to reduce burden (emergency visits,
avoidable hospitalisations, disability and costs) while improving quality of life worldwide, and, in the longer
term, to reduce disease incidence by new and innovative prevention strategies.
AIRWAYS-ICPs has a clear strategic relevance with regard to the EU Health Strategy as it will bring added
value to the existing public health knowledge:
N To propose a common framework for chronic respiratory disease (and for comorbidities) ICPs for
the entire EU which can then be expanded to other regions (e.g. the Commonwealth of Independent
States) and which will allow comparability and trans-national initiatives.
N To help risk stratification in chronic respiratory disease patients, using a common strategy.
N To develop cost-effective policies, in particular strengthening those on smoking and environment
exposure.
N To have a significant implication on the health of citizens in the short term (reduction of morbidity,
improvement of education in children and of work in adults) and in the long term (healthy ageing).
N To propose a common simulation tool for the entire EU in order to assist physicians in the
segmentation of patients and in the choice of pathways.
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Canada), A. Bourdin (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région
Languedoc Roussillon; UM1, University 1, Montpellier; and INSERM, U1046, France), R. Bourret (University Hospital
Montpellier; and MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France),
P.J. Bousquet (ARIA, Allergic Rhinitis and Its Impact on Asthma), A. Bręborowicz (Polish Alliance against Chronic
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Doenças Respiratórias, Portugal), J. Gomez Vera (Colegio Mexicano de Inmunologı́a Clı́nica y Alergia), M. Gonsalves
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Korea), D. Jurásková (CARO, Czech Alliance against Chronic Respiratory Diseases; Pneumological Section of
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Mexico), A. Shaik (NHS Scotland, Glasgow, UK), A. Sheikh (Allergy and Respiratory Research Group, Centre for
Population Health Sciences, The University of Edinburgh, Medical School, Edinburgh, UK; and Division of General Internal
Medicine and Primary Care, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA), M. Shields
(Child Health, Queen’s University Belfast and Royal Belfast Hospital for Sick Children, UK), N. Siafakas (Dept of Thoracic
Medicine, University Hospital of Heraklion, Heraklion, Greece), Y. Sibille (University Hospital of Mont-Godinne, Catholic
University of Louvain, Yvoir, Belgium), P. Śliwiński (Polish Alliance against Chronic Respiratory Diseases), T. Similowski
(Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1158 ‘‘Neurophysiologie Respiratoire Expérimentale et Clinique’’,
Paris; INSERM, UMR_S 1158 ‘‘Neurophysiologie Respiratoire Expérimentale et Clinique’’, Paris; AP-HP, Groupe
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